New drug cocktail may spare kidney removal in High-Risk bladder cancer patients
NCT ID NCT06822010
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a two-drug combination (gemcitabine and Jelmyto) given in sequence to treat a high-risk type of upper urinary tract cancer. The goal is to destroy the tumor without removing the kidney, which is the usual treatment. About 28 adults with non-invasive, high-grade cancer will receive the drugs through a tube into the kidney. Researchers will check if the cancer disappears completely and monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of a rare cancer?
- New oral drug targets Cancer's growth engine in advanced tumours
- Could an ALS drug clear the fog of chemo brain?
- Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
- A simple urine test could revolutionize bladder cancer detection
- New drug combo aims to tackle Hard-to-Treat HER2 cancers